Compare Solaredge Technologies Inc (SEDG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Solaredge Technologies Inc trades at $32.21 (market cap $2.00B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.5× Solaredge Technologies Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SEDG | ZBH | |
|---|---|---|
Market Cap | $2.00B | $16.95B |
Volume | 2,739,860 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $78.51 | $103.98 |
52-Week Low | $28.47 | $79.58 |
Typical Hold Time | 34 Days | 89 Days |
Enterprise Value | $1.86B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.47, down 2.08% amid bearish technical signals and ongoing financial challenges. The company reported a net loss of $405 million in 2025 with negative profit margins, though revenue showed some recovery to $1.18 billion. Recent news highlights multiple law firm investigations into investor claims while the company pursues AI data center expansion opportunities.
The outlook remains challenging with significant execution risks and negative profitability, though analyst consensus suggests modest upside potential to the $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures in solar markets, and the company's ability to achieve its ambitious 2029 revenue target of $2.4 billion.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
